

## Frank C. Sciavolino, Ph.D. is Appointed Executive Vice President of Indigene Global Design and Development

*Indigene News*  
July 19, 2007

Indigene Global Development and Design is developing IG-RD-001, a novel therapeutic agent for the treatment of respiratory diseases, and IG-MD-009 for the treatment of diabetes and its complications. In addition to IG-RD-001 and IG-MD-009, we expect to nominate four additional development candidates during the next few months to address the pathologic conditions associated with metabolic syndrome and glycemic control. And going beyond respiratory diseases, diabetes, and metabolic syndrome, we will continue to build our Rx product development portfolio through internal discovery initiatives and licensing opportunities.

In order to effectively manage this growing collection of research, development and regulatory activities, and leverage our international capabilities, it has now become essential to formally establish a research and development organization within the Company. Accordingly, I am announcing today the formation of Indigene Global Design and Development. I am also pleased to announce the appointment of Dr. Frank C. Sciavolino to the new position of Executive Vice President, Indigene Global Design and Development (GD&D), reporting to me. As worldwide head of GD&D, Dr. Sciavolino will assume responsibility for the technical direction, management, and staffing of all indigene design and development operations. Over the course of the next few months, Dr. Sciavolino will announce details of the new Global D&D organization and appointments to key positions.

Dr. Sciavolino joined Indigene in November 2003 as Vice President, Product Development and Regulatory Affairs. He holds a Ph.D. in organic chemistry from The University of Michigan and B. S. in Pharmacy (magna cum laude) from St. John's University. After completing post-doctoral studies in organic chemistry at the University of Illinois, he joined the research staff of Pfizer where he held positions of increasing technical and managerial responsibility in discovery, development, and licensing operations. Over the course of Frank's 35-year career at Pfizer, he was the enabling force behind two of Pfizer's most notable franchises, Zithromax and the Cox-2 Alliance with Pharmacia. During their peak years, the combined sales of Zithromax and the Cox-2 inhibitors, Celebrex and Bextra, were contributing more than \$5 billion annually to Pfizer top-line revenues.

Dr. Sciavolino is a rare and unique individual with an understanding of drug research that spans discovery, development, and licensing operations. He is a seasoned medicinal chemist, a negotiator, an articulate spokesperson, and the consummate diplomat with a stately and distinguished presence in representing Indigene worldwide.